Skip to main content

Table 1 Baseline characteristics of postmenopausal women with T2DM

From: Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus

  Osteoporosis n = 21 Osteopenia n = 47 Normal BMD n = 49 p
Age (year) 65,3 ± 10,2 67,4 ± 8,04 64,9 ± 8,7 NS
Waist (cm) 89,8 ± 11,2 96,0 ± 8,2 98,3 ± 12,0 c 0,03; b 0,003
BMI (kg/m2) 27,5 ± 5,6 29,1 ± 3,9 31,3 ± 5,1 a 0,02; b 0,002
Menopause duration (year) 17,8 ± 9,2 18,3 ± 8,5 14,7 ± 7,9 a 0,049
Diabetes duration (year) 9,1 ± 6,3 12,2 ± 7,1 12,1 ± 7,3 NS
HbA1c (%) 10,2 ± 2,24 10,1 ± 1,59 9,95 ± 1,9 NS
Cholesterol (mmol/l) 5,45 ± 1,62 5,13 ± 1,25 4,97 ± 1,41 NS
HDL cholesterol (mmol/l) 1,29 ± 0,25 1,22 ± 0,25 1,19 ± 0,27 NS
LDL cholesterol (mmol/l) 3,39 ± 1,02 3,03 ± 1,02 2,76 ± 1,12 ab 0,042
Triglicerydes (mmol/l) 1,98 ± 1,32 1,96 ± 0,79 2,37 ± 1,43 NS
Osteocalcin (ng/ml) 10,22 ± 7,67 8,37 ± 3,84 6,32 ± 2,87 a 0,025; b 0,0013
Insulin (mIU/l) 8,94 ± 4,14 9,97 ± 4,82 10,62 ± 5,69 NS
Pyrilinks (nMPD/mMc) 7,8 ± 3,1 7,41 ± 2,9 5,5 ± 2,1 a 0,001; b 0,0015
Crosslaps (ng/ml) 0,54 ± 0,25 0,49 ± 0,29 0,35 ± 0,21 a 0,012; b 0,0092
PAI-1 (U/l) 3,3 ± 2,1 3,5 ± 2,1 4,4 ± 1,9 a 0,042; b0,052
Fibrinogen (g/L) 4,1 ± 1,0 4,3 ± 0,8 4,0 ± 0,8 NS
CRP (mg/L) 5,77 ± 11,6 3,89 ± 3,67 3,74 ± 4,25 NS
Lumbar BMD (g/cm2) 0,707 ± 0,07 0,856 ± 0,04 1,036 ± 0,09 ab c <0,05
Hip BMD (g/cm2) 0,746 ± 0,13 0,838 ± 0,109 0,985 ± 0,147 ac b <0,05
  1. Chi square test; BMD bone mineral density, BMI body mass index, HDL high density lipoprotein, LDL low density lipoprotein, PAI 1 plasminogen activator inhibitor 1. Bolded p values are significant.
  2. aosteoporosis group vs. normal BMD group; bosteopenia vs. normal BMD group; costeoporosis vs. osteopenia group